NASDAQ:LMNX

Luminex Stock Forecast, Price & News

$36.86
-0.05 (-0.14 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.81
$36.99
50-Day Range
$31.20
$37.03
52-Week Range
$20.61
$41.69
Volume648,400 shs
Average Volume1.05 million shs
Market Capitalization$1.74 billion
P/E Ratio94.52
Dividend Yield1.09%
Beta0.61
30 days | 90 days | 365 days | Advanced Chart
Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Luminex and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020
Employees1,325
Year FoundedN/A

Sales & Book Value

Annual Sales$334.64 million
Cash Flow$0.59 per share
Book Value$10.32 per share

Profitability

Net Income$-3,840,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$1.74 billion
Next Earnings Date8/3/2021 (Estimated)
OptionableOptionable

Headlines

See More Headlines
Luminex logo

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

580th out of 2,042 stocks

Surgical & Medical Instruments Industry

56th out of 169 stocks

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.8Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Luminex (NASDAQ:LMNX) Frequently Asked Questions

Is Luminex a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Luminex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNX, but not buy additional shares or sell existing shares.
View analyst ratings for Luminex
or view top-rated stocks.

What stocks does MarketBeat like better than Luminex?

Wall Street analysts have given Luminex a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Luminex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Luminex?

Luminex saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 2,380,000 shares, a drop of 22.2% from the March 31st total of 3,060,000 shares. Based on an average trading volume of 1,140,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 5.4% of the company's stock are sold short.
View Luminex's Short Interest
.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Luminex
.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings data on Sunday, February, 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.13 by $0.12. The medical instruments supplier earned $111.39 million during the quarter, compared to analysts' expectations of $104.57 million. Luminex had a net margin of 4.60% and a trailing twelve-month return on equity of 3.75%. The firm's quarterly revenue was up 23.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.07 earnings per share.
View Luminex's earnings history
.

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMNX stock has increased by 36.0% and is now trading at $36.86.
View which stocks have been most impacted by COVID-19
.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Tuesday, February 9th. Shareholders of record on Thursday, March 25th will be paid a dividend of $0.10 per share on Thursday, April 15th. This represents a $0.40 annualized dividend and a yield of 1.09%. The ex-dividend date of this dividend is Wednesday, March 24th.
View Luminex's dividend history
.

Is Luminex a good dividend stock?

Luminex pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.09%.
View Luminex's dividend history.

What price target have analysts set for LMNX?

3 brokerages have issued 1-year price targets for Luminex's shares. Their forecasts range from $37.00 to $37.00. On average, they expect Luminex's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Luminex
or view top-rated stocks among Wall Street analysts.

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, Chairman, CEO & Pres (Age 67, Pay $1.91M)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 59, Pay $824.12k)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 53, Pay $693.94k)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 51, Pay $660.42k)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 59, Pay $633.57k)
  • Mrs. Kendel B. Martin CPA, VP of Accounting
  • Jeff Christensen, Sr. Director of Investor Relations
  • Mr. Eric S. Shapiro, Sr. VP of Global Marketing (Age 57)
  • Ms. Nancy M. Fairchild, Sr. VP of HR (Age 67)
  • Dr. Charles J. Collins, Sr. VP of R&D (Age 44)

What is Nachum “Homi” Shamir's approval rating as Luminex's CEO?

53 employees have rated Luminex CEO Nachum “Homi” Shamir on Glassdoor.com. Nachum “Homi” Shamir has an approval rating of 87% among Luminex's employees.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Square (SQ), Marvell Technology Group (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.54%), Copeland Capital Management LLC (3.03%), Cowen Prime Services LLC (0.38%), Envestnet Asset Management Inc. (0.35%), Rhumbline Advisers (0.28%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.27%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, Randall Myers, Richard W Rew II and Stephen L Eck.
View institutional ownership trends for Luminex
.

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., State of New Jersey Common Pension Fund D, Dupont Capital Management Corp, Quantitative Systematic Strategies LLC, State of Alaska Department of Revenue, Strs Ohio, Fisher Asset Management LLC, and Texas Permanent School Fund. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex
or view top insider-selling stocks.

Which institutional investors are buying Luminex stock?

LMNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Copeland Capital Management LLC, BCK Capital Management LP, Envestnet Asset Management Inc., Migdal Insurance & Financial Holdings Ltd., Juncture Wealth Strategies LLC, and Exchange Traded Concepts LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Nachum Shamir, and Stephen L Eck.
View insider buying and selling activity for Luminex
or or view top insider-buying stocks.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $36.86.

How much money does Luminex make?

Luminex has a market capitalization of $1.74 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Luminex have?

Luminex employs 1,325 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

Where are Luminex's headquarters?

Luminex is headquartered at 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


This page was last updated on 5/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.